{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T08:31:51Z","timestamp":1794299511698,"version":"4.9.0"},"reference-count":14,"publisher":"BMJ","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["BMJ Case Reports"],"abstract":"<jats:p>The authors report the case of an 80-year-old man who had heavily pretreated castration refractory carcinoma of the prostate and heart failure. Following the introduction of spironolactone to manage his heart failure, the patient experienced clinical and biochemical progression of his prostate cancer. Within 2 weeks of withdrawing spironolactone the patient\u2019s prostate-specific antigen returned its previous level. This is the first reported case of clinical and biochemical progression of prostate cancer following the introduction of spironolactone. The authors propose that spironolactone is a selective androgen receptor modulator. Spironolactone should be used in caution with men with prostate cancer, and should not be used to treat oedema, hypokalaemia and hypertension associated with the newly licensed hormonal therapy abiraterone acetate.<\/jats:p>","DOI":"10.1136\/bcr.11.2011.5238","type":"journal-article","created":{"date-parts":[[2012,2,28]],"date-time":"2012-02-28T14:19:33Z","timestamp":1330438773000},"page":"bcr1120115238","source":"Crossref","is-referenced-by-count":33,"title":["Spironolactone, a possible selective androgen receptor modulator, should be used with caution in patients with metastatic carcinoma of the prostate"],"prefix":"10.1136","volume":"2012","author":[{"given":"Santhanam","family":"Sundar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter D","family":"Dickinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2012,2,28]]},"reference":[{"key":"2025042701342267000_2012.feb25_1.bcr1120115238.1","unstructured":"Prescription Cost Analysis, England \u2013 2010. http:\/\/www.ic.nhs.uk\/statistics-and-data-collections\/primary-care\/prescriptions\/prescription-cost-analysis-england--2010 (accessed 7 November 2011)."},{"key":"2025042701342267000_2012.feb25_1.bcr1120115238.2","unstructured":"Cancer research UK: Cancerstats. Incidence and prevalence of prostate cancer. http:\/\/info.cancerresearchuk.org\/cancerstats\/types\/prostate\/incidence (accessed 7 November 2011)."},{"key":"2025042701342267000_2012.feb25_1.bcr1120115238.3","doi-asserted-by":"crossref","unstructured":"Scher HI Logothetis C Molina A . Improved survival outcomes in clinically relevant patient subgroups from COU-AA-301, a phase III study of abiraterone acetate (AA) plus prednisone (P) in patients with metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel-based chemotherapy. J Clin Oncol 2011;29:(suppl 7; abstr 4).","DOI":"10.1200\/jco.2011.29.7_suppl.4"},{"key":"2025042701342267000_2012.feb25_1.bcr1120115238.4","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.29.5170"},{"key":"2025042701342267000_2012.feb25_1.bcr1120115238.5","doi-asserted-by":"publisher","DOI":"10.1210\/jcem-59-1-51"},{"key":"2025042701342267000_2012.feb25_1.bcr1120115238.6","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1982.03320340049034"},{"key":"2025042701342267000_2012.feb25_1.bcr1120115238.7","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.1986.tb05722.x"},{"key":"2025042701342267000_2012.feb25_1.bcr1120115238.8","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1016\/S0021-9258(17)37833-X","article-title":"Studies on the destruction of adrenal and testicular cytochrome P-450 by spironolactone. Requirement for the 7alpha-thio group and evidence for the loss of the heme and apoproteins of cytochrome P-450.","volume":"254","author":"Menard","year":"1979","journal-title":"J Biol Chem"},{"key":"2025042701342267000_2012.feb25_1.bcr1120115238.9","doi-asserted-by":"publisher","DOI":"10.1055\/s-0028-1087188"},{"key":"2025042701342267000_2012.feb25_1.bcr1120115238.10","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/S0022-5347(17)67001-0","article-title":"Suppression of plasma androgens by spironolactone in castrated men with carcinoma of the prostate.","volume":"114","author":"Walsh","year":"1975","journal-title":"J Urol"},{"key":"2025042701342267000_2012.feb25_1.bcr1120115238.11","doi-asserted-by":"publisher","DOI":"10.1016\/j.purol.2009.04.002"},{"key":"2025042701342267000_2012.feb25_1.bcr1120115238.12","doi-asserted-by":"publisher","DOI":"10.1016\/0022-4731(88)90295-6"},{"key":"2025042701342267000_2012.feb25_1.bcr1120115238.13","doi-asserted-by":"publisher","DOI":"10.1038\/79637"},{"key":"2025042701342267000_2012.feb25_1.bcr1120115238.14","doi-asserted-by":"crossref","first-page":"3172","DOI":"10.1200\/JCO.2000.18.17.3172","article-title":"Selective estrogen receptor modulators: structure, function, and clinical use.","volume":"18","author":"Osborne","year":"2000","journal-title":"J Clin Oncol"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr.11.2011.5238","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,27]],"date-time":"2025-04-27T08:34:31Z","timestamp":1745742871000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr.11.2011.5238"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,2,28]]},"references-count":14,"alternative-id":["10.1136\/bcr.11.2011.5238"],"URL":"https:\/\/doi.org\/10.1136\/bcr.11.2011.5238","relation":{},"ISSN":["1757-790X"],"issn-type":[{"value":"1757-790X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,2,28]]}}}